High-Dimensional Spatial Profiling of the Tumor Immune Microenvironment (TME) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Predictive Biomarkers of Immunotherapy
HNSCC remains a challenging malignancy, with only a subset of patients benefiting from PD-1/PD-L1 blockade immunotherapy. Despite clinical advances, reliable predictive biomarkers to guide patient selection and improve outcomes are urgently needed. Current strategies often rely on PD-L1 expression or tumor mutational burden, but these lack sufficient specificity and sensitivity. The aim of the study […]
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
